Get Mad, Then Average Down Real Money Pro($)

Sometimes a buy goes against you, even if the fundamentals are solid.
I'm considering two price support clusters for a possible entry.
I'm looking at it closely for a buy entry.
The company is a steady grower, but its stock has swooned.
The medical technology firm's acquisitions are starting to pay off. 
As more people get health insurance, this stock should prove to be a steady grower.
Span-America Medical provides an attractive risk-reward scenario.
Hologic should benefit from a greater sense of urgency.
The sector is not for the investor who abhors volatility.
These four names are soaring, and I'd jump into all of them, even after their recent runs.

Columnist Conversations

We are currently testing the key resistance decision in ICE. Do not consider an entry without a trigger!! ...
Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Before: Transparency is...
EA reported June revenue of $775 mlm vs. $714 est. much better than expected. EPS of $0.19 blew away the St es...
BIDU still has some higher targets, but it's a good idea to TRAIL UP stops when you EXTEND the prior swings. ...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.